Status and phase
Conditions
Treatments
About
This phase3 study is a randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of Lemzoparlimab for injection in combination with AZA versus AZA monotherapy as first-line therapy in treatment-naïve subjects with intermediate- and high-risk MDS.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10 participants in 2 patient groups
Loading...
Central trial contact
Shuang Li
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal